IRIS
PALUMBO, Giuseppe Alberto Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.281
EU - Europa 7.228
AS - Asia 7.164
SA - Sud America 1.202
AF - Africa 824
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 8
AN - Antartide 1
Totale 29.728
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.878
SG - Singapore 3.683
RU - Federazione Russa 2.527
CN - Cina 1.866
IT - Italia 1.670
BR - Brasile 996
IE - Irlanda 967
UA - Ucraina 578
VN - Vietnam 563
CI - Costa d'Avorio 412
FR - Francia 376
KR - Corea 325
CA - Canada 301
DE - Germania 185
IN - India 176
GB - Regno Unito 172
NG - Nigeria 167
SE - Svezia 163
FI - Finlandia 117
AR - Argentina 89
NL - Olanda 81
HK - Hong Kong 78
SN - Senegal 77
MX - Messico 74
JP - Giappone 69
PL - Polonia 68
BD - Bangladesh 66
ES - Italia 60
BE - Belgio 55
ZA - Sudafrica 49
IQ - Iraq 48
CH - Svizzera 45
TR - Turchia 37
BJ - Benin 33
CZ - Repubblica Ceca 33
PK - Pakistan 30
UZ - Uzbekistan 27
AT - Austria 26
ID - Indonesia 25
EC - Ecuador 23
CO - Colombia 22
LT - Lituania 22
MA - Marocco 21
CL - Cile 19
EG - Egitto 19
JO - Giordania 19
LB - Libano 19
VE - Venezuela 19
AU - Australia 18
GR - Grecia 18
KE - Kenya 17
AE - Emirati Arabi Uniti 15
IR - Iran 15
IL - Israele 13
DZ - Algeria 12
MY - Malesia 11
PH - Filippine 11
PY - Paraguay 11
SA - Arabia Saudita 11
OM - Oman 10
BG - Bulgaria 9
PE - Perù 9
RO - Romania 9
AZ - Azerbaigian 7
EU - Europa 7
HR - Croazia 7
TT - Trinidad e Tobago 7
AL - Albania 6
KZ - Kazakistan 6
NP - Nepal 6
PS - Palestinian Territory 6
UY - Uruguay 6
ET - Etiopia 5
KG - Kirghizistan 5
RS - Serbia 5
BO - Bolivia 4
CY - Cipro 4
DO - Repubblica Dominicana 4
SI - Slovenia 4
AM - Armenia 3
BY - Bielorussia 3
GT - Guatemala 3
GY - Guiana 3
HN - Honduras 3
JM - Giamaica 3
LV - Lettonia 3
MT - Malta 3
NI - Nicaragua 3
NO - Norvegia 3
PT - Portogallo 3
TN - Tunisia 3
AO - Angola 2
EE - Estonia 2
HU - Ungheria 2
KW - Kuwait 2
LU - Lussemburgo 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
AQ - Antartide 1
BB - Barbados 1
Totale 29.705
Salva come PNG Salva come JPEG
Città #
Dallas 2.304
Singapore 2.266
Santa Clara 1.501
Moscow 1.129
Dublin 939
Chandler 923
San Jose 898
Houston 799
Ashburn 744
Chicago 539
Jacksonville 536
Hefei 453
Abidjan 412
Boardman 386
Catania 353
Seoul 325
Lauterbourg 288
Los Angeles 284
Beijing 252
Lawrence 248
Cambridge 245
Andover 241
Nanjing 212
Ho Chi Minh City 182
Toronto 163
Council Bluffs 159
Civitanova Marche 132
Des Moines 129
Hanoi 122
New York 116
Buffalo 112
São Paulo 108
Wilmington 107
Milan 100
Rome 94
San Mateo 90
Abuja 80
Dakar 77
Lagos 76
Palermo 73
Nanchang 72
Hong Kong 66
The Dalles 63
Lappeenranta 59
Florence 58
Shenyang 58
Saint Petersburg 57
Warsaw 57
Tokyo 56
Hebei 54
Orem 53
Jiaxing 52
Montreal 52
Brussels 51
Columbus 51
Ottawa 50
Grafing 46
Amsterdam 45
Chennai 45
Munich 45
Changsha 41
Stockholm 41
Brooklyn 40
Dong Ket 40
Washington 40
Boston 39
Helsinki 35
London 35
Seattle 35
Tianjin 34
Cotonou 33
Denver 33
Atlanta 32
Paris 31
Falls Church 29
Johannesburg 28
Poplar 28
Rio de Janeiro 28
Messina 27
Phoenix 27
Mumbai 25
Naples 25
San Francisco 25
Manchester 24
Mexico City 24
Turku 23
Kochi 22
Belo Horizonte 21
Haiphong 21
Frankfurt am Main 19
Baghdad 18
Bronte 18
Den Haag 18
Amman 17
Bari 17
Curitiba 17
Querétaro 17
Redondo Beach 17
Brno 16
Bremen 15
Totale 20.362
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 290
Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes 247
Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population 238
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 216
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 203
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 200
IGFBP-6 Alters Mesenchymal Stromal Cell Phenotype Driving Dasatinib Resistance in Chronic Myeloid Leukemia 196
A cytoprotective role for the heme oxygenase-1/CO pathway during neural differentiation of human mesenchymal stem cells 185
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 183
ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis 181
Focus on Osteosclerotic Progression in Primary Myelofibrosis 180
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 177
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis 176
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 175
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 170
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 168
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 167
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports 166
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 164
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 161
Hedgehog signaling pathways in multiple myeloma 160
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 159
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 158
A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study 157
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 156
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 155
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia 153
A case of high-risk AML in a patient with advanced systemic mastocytosis 153
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma 152
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 152
Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis Patients 149
In vitro apoptotic response of freshly isolated chronic myeloid leukemia cells to all-trans retinoic acid and cytosine arabinoside 149
A physiological role for the neuropeptide luteinizing hormone-releasing hormone (LHRH) during the maturation of thymus Gland function 148
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 148
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 146
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 146
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 142
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 142
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI) 142
Neuroprotective Role of α-Lipoic Acid in Iron-Overload-Mediated Toxicity and Inflammation in In Vitro and In Vivo Models 141
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 141
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 139
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 137
Bortezomib Could Reduce Cell Viability by Activation of Heme Oxygenase 1 in Multiple Myeloma Cells 137
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 137
Correction to: Neuroprotective Role of α-Lipoic Acid in Iron-Overload-Mediated Toxicity and Inflammation in In Vitro and In Vivo Models (Antioxidants, (2022), 11, 8, (1596), 10.3390/antiox11081596) 136
13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia 136
Multiple Myeloma in 2023 Ways: From Trials to Real Life 135
Renal extramedullary hematopoiesis as an epiphenomenon of bone marrow dysfunction in a patient with primary myelofibrosis: A rare case report 135
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 134
Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience 133
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 132
Correction: TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma (Cell Death & Disease, (2019), 10, 10, (704), 10.1038/s41419-019-1959-5) 130
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases 129
Effects of micronised microencapsulated ferric pyrophosphate supplementation in patients with advanced cancer and iron deficiency: A single-centre cohort pilot study 129
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 126
Terapia del mieloma multiplo 126
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. 126
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions 125
Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation 125
Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field 124
Engagement of Mesenchymal Stromal Cells in the Remodeling of the Bone Marrow Microenvironment in Hematological Cancers 123
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 122
Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology 122
Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia 122
Low serum levels of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in IFN-treated chronic myeloid leukemia (CML) patients 122
Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients 121
ANTITUMOR ACTIVITY OF BORTEZOMIB ALONE AND IN COMBINATION WITH TRAIL IN HUMAN ACUTE MYELOID LEUKEMIA C.M.S 121
The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents 121
Angiogenic factors (VEGF, bFGF, and HGF) in multiple myeloma: higher levels in bone marrow than in peripheral blood 120
Antitumor Activity of Bortezomib Alone and in Combination with TRAIL in Human Acute Myeloid Leukemia 120
Nuclear translocation of Heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells 119
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting 118
MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes 117
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint 117
Emangioma, plasmocitoma e mieloma multiplo del rachide 117
Pyrrolidinedithiocarbamate induces apoptosis in human acute myelogenous leukemic cells affecting NF-kappaB activity 116
The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma 116
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 116
AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib 115
Angiogenesis in acute myeloid leukemia 114
Evaluation of taxol cytotoxicity on B-CLL cells in vitro 114
Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality 113
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future 112
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis 112
5-AZACYTIDINE FOR THE TREATMENT OF INTERMEDIATE-2/HIGH IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 83 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM 112
Emergencies in Hematology: Why, When and How I Treat? 111
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data 111
HIGH-RESOLUTION SNP ARRAYS AS AN ADDITIONAL TOOL TO SEARCH FOR GENETIC DEFECTS INVOLVED IN PROGRESSION FROM MYELODYSPLASTIC SINDROME TO ACUTE LEUKEMIA 111
Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters 110
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 109
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases 108
Emerging Therapeutic Approaches for Anemia in Myelofibrosis 108
Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview 108
Different in vitro alemtuzumab induced apoptosis on T and B lymphocytes of B-CLL patients 107
Proteomic analysis reveals autophagy as pro-survival pathway elicited by long-term exposure with 5-azacitidine in high-risk myelodysplasia 107
Endoscopic features of gastro-intestinal lymphomas: From diagnosis to follow-up 106
IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis 106
Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes 105
Effects of proton irradiations on functional characteristics of bone marrow mesenchimal stem cells 105
Totale 14.077
Salva come PNG Salva come JPEG
Categoria #
all - tutte 97.869
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 97.869
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021209 0 0 0 0 0 0 0 0 0 12 117 80
2021/20221.799 150 246 2 13 363 38 271 77 158 32 35 414
2022/20233.042 278 147 73 212 249 522 28 515 738 56 154 70
2023/20241.805 111 246 93 127 87 339 97 133 10 51 320 191
2024/20256.208 56 954 344 315 1.336 633 219 234 442 614 527 534
2025/202614.000 863 1.302 2.177 908 2.238 2.888 1.607 358 864 795 0 0
Totale 30.241